What sectors does Ascendis Pharma A/S focus on?

Ascendis Pharma A/S focuses on Biotech.

Where is Ascendis Pharma A/S located?

Ascendis Pharma A/S is headquartered in Hellerup, DK.

Ascendis Pharma A/S

operating company · company profile

Hellerup · 17 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Ascendis Pharma A/S

Each arrow is one introduction. Sign up to fill in the first one.

1,125 people can intro you to Erik

Ask Gina Domanig to introduce you to Erik Steffensen

You →Gina · together at Innovation Fund Denmark →Erik

409 people can intro you to Jethro

Ask Jamie Chen to introduce you to Jethro Ekuta

You →Jamie · together at Horizon →Jethro

213 people can intro you to Albert

Ask Sam Okafor to introduce you to Albert Cha

You →Sam · together at Vivo Capital →Albert

Sherrie Glass102 people can intro you
Flemming Steen Jensen80 people can intro you
Jan Møller Mikkelsen79 people can intro you

Your email: who you already know at Ascendis Pharma A/S, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ascendis Pharma A/S team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

Ascendis Pharma employs an innovation algorithm to identify unmet medical needs where clinically validated parent drugs align with its TransCon technology platform. The company focuses on building a pipeline of therapeutic candidates primarily in endocrinology rare diseases and oncology, aiming to create therapies that meaningfully improve patient outcomes.

Invests inBiotech Copenhagen Denmark Europe Germany Hellerup North America San Francisco

Source: firm website, verified Sep 27, 2026.

Leave your own feedback

Hellerup, DK

Founded

2007

Team · 17 people

from the firm's website & curated & public directories

Jan Møller Mikkelsen· President and CEO· San Francisco Bay Areain

Founder of Ascendis Pharma in 2007 and its President and CEO. Previously led LifeCycle Pharma, headed Maxygen's Pharmaceutical Division, co-founded ProFound Pharma, and held senior roles at Novo Nordisk.

Aimee D. Shu· Executive Vice President, Chief Medical Officer

EVP and Chief Medical Officer since November 2024, leading clinical development and medical affairs. A practicing endocrinologist at Stanford University Health Care.

Bill Fairey· Board Member

Board member since 2022 and Executive Chairman of Respira Therapeutics. Previously held commercial and operating roles at MyoKardia, ChemoCentryx, and Actelion Pharmaceuticals.

Flemming Steen Jensen· Executive Vice President, Product Supply and Quality· Copenhagen Metropolitan Areain

EVP of Product Supply and Quality, having led the function since 2015. Previously at NNE Pharmaplan and ALK-Abelló.

Jay Donovan Wu· Executive Vice President, President US Market

EVP and President of Ascendis US since January 2025, leading the US organization. Previously spent 13 years at Genentech, most recently as VP and Head of Rare Diseases.

Jean-Jacques Bienaimé· Board Memberin

Board member and former longtime CEO and Chair of BioMarin Pharmaceutical. Previously led Genencor and SangStat Medical Corporation.

Jethro Ekuta· Chief Regulatory & Safety Officer· Greater Philadelphiain

Chief Regulatory & Safety Officer since November 2024, heading Global Regulatory Affairs & Pharmacovigilance. Formerly held regulatory leadership roles at Alexion/AstraZeneca and Horizon Therapeutics.

Kennett Sprogøe· Executive Vice President, Head of Research & Product Development

EVP and Head of Research & Product Development, with the company since 2007. Holds a Ph.D. in Natural Products Chemistry from the University of Copenhagen.

Lars Holtug· Board Member· Copenhagen, Capital Region of Denmark, Denmarkin

Board member since 2018. Former partner and Denmark chairman at PricewaterhouseCoopers, with expertise auditing listed pharmaceutical and biotech companies.

Lisa Bright· Board Member

Board member since 2017. Former President International at Intercept Pharmaceuticals, with earlier leadership roles at Gilead Sciences and GlaxoSmithKline.

Lotte Sønderbjerg· Executive Vice President, Chief Administration Officerin

EVP and Chief Administration Officer since 2007 and Managing Director of Ascendis Pharma GmbH. Previously held HR and finance roles at LifeCycle Pharma and Acadia Pharmaceuticals.

Michael Wolff Jensen· Executive Vice President, Chief Legal Officer

EVP and Chief Legal Officer since January 2023, with the company since 2013. Former Ascendis board chairman and acting CFO; previously held finance and legal roles at Ørsted, LifeCycle Pharma, and Genmab.

Scott Smith· Executive Vice President, Chief Financial Officer

EVP and CFO since January 2023, with the company since 2016. Previously led healthcare investment banking at Wedbush Securities and was a director at Merrill Lynch.

Sherrie Glass· Chief Business Officer· New York City Metropolitan Areain

Chief Business Officer since September 2024, overseeing business development, global marketing, and commercial operations. Previously SVP of Enterprise Strategy at Bristol Myers Squibb.

Siham Imani· Board Member

Board member since 2022 and Head of Global Strategy, Business Development, Shared Value & Sustainability at Chiesi. Previously held corporate strategy roles at Servier and Ipsen.

Albert Cha· Chairman· Palo Altoin

Chairman of the Board since 2021 and a director since 2014. A Managing Partner on Frazier's Life Sciences team with over 20 years of biopharmaceutical and medical device investing experience; previously a Managing Partner at Vivo Capital.

albert@frazierls.com

Erik Steffensen· External Consultant CMC and Combination Products· Copenhagen, Capital Region of Denmark, Denmarkin

Director of R&D, Manufacturing and Quality at Novo Nordisk with over 20 years of leadership experience and degrees from Harvard, IMD, and London Business School.

Frequently asked questions

What sectors does Ascendis Pharma A/S focus on?: Ascendis Pharma A/S focuses on Biotech.
Where is Ascendis Pharma A/S located?: Ascendis Pharma A/S is headquartered in Hellerup, DK.

Images

Similar investors

8VC

8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.

$500K – $50M

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

$500K – $50M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Website & social